| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| GM-CSF R alpha | HOT GRA-H52H7 | Human GM-CSF R alpha Protein, His Tag (SPR verified) | Human | HEK293 | ![]() | SDS-PAGE | $340.00 100ug | ||
| GM-CSF R alpha | Mouse GM-CSF R alpha Protein, His Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $360.00 100ug | |||
| GM-CSF R alpha | Human GM-CSF R alpha Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $340.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mavrilimumab | CAM-3001; KPL-301; GM-CSFR; CAM3001 | Phase 3 Clinical | Csl Ltd | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Giant Cell Arteritis; Pneumonia | Details |
| Anti-GMR CAR T-cell Therapy | Phase 2 Clinical | Kyoto Prefectural University Of Medicine, Shinshu University School of Medicine | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile | Details | |
| CSF2RA gene-corrected macrophages(University of South Florida) | Phase 2 Clinical | Russian Academy Of Medical Sciences | Pulmonary Alveolar Proteinosis | Details | |
| STSA-1005 | STSA-1005; STSA1005 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |